878 related articles for article (PubMed ID: 21288094)
1. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Penny ME; Aranda C; Vardas E; Moi H; Jessen H; Hillman R; Chang YH; Ferris D; Rouleau D; Bryan J; Marshall JB; Vuocolo S; Barr E; Radley D; Haupt RM; Guris D
N Engl J Med; 2011 Feb; 364(5):401-11. PubMed ID: 21288094
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
4. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
[TBL] [Abstract][Full Text] [Related]
8. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
9. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
Olsson SE; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Hum Vaccin; 2009 Oct; 5(10):696-704. PubMed ID: 19855170
[TBL] [Abstract][Full Text] [Related]
11. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
Yoshikawa H; Ebihara K; Tanaka Y; Noda K
Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
Garnock-Jones KP; Giuliano AR
Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
18. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
Castellsagué X; Muñoz N; Pitisuttithum P; Ferris D; Monsonego J; Ault K; Luna J; Myers E; Mallary S; Bautista OM; Bryan J; Vuocolo S; Haupt RM; Saah A
Br J Cancer; 2011 Jun; 105(1):28-37. PubMed ID: 21629249
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.
Wei L; Xie X; Liu J; Zhao Y; Chen W; Zhao C; Wang S; Liao X; Shou Q; Qiu Y; Qiao Y; Saah AJ
Vaccine; 2019 Jun; 37(27):3617-3624. PubMed ID: 30122646
[TBL] [Abstract][Full Text] [Related]
20. HPV vaccine against HPV infection and disease in males.
Wieland U; Kreuter A
N Engl J Med; 2011 Jun; 364(22):2163; author reply 2164-5. PubMed ID: 21631334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
